Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IB Open-Label Rising-Dose Study of Biomed 101 in Patients Treated With Interleukin-2 for Malignancy

NCT00004890 is registered in ClinicalTrials.gov with BioMedicines as lead sponsor.

NCT NCT00004890
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00004890 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IB Open-Label Rising-Dose Study of Biomed 101 in Patients Treated With Interleukin-2 for Malignancy
Lead sponsor
BioMedicines
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2000
Completion date
December 31, 2002
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

drug extravasation, kidney cancer